Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.

For additional information on GAAP to non-GAAP reconciliation see: https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/

Non-GAAP Financial Measures

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company’s financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

<table>
<thead>
<tr>
<th></th>
<th>Fiscal Year 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP diluted earnings per share</td>
<td>$0.31 - $0.36</td>
</tr>
<tr>
<td>Acquisition – amortization of intangible assets</td>
<td>$0.48</td>
</tr>
<tr>
<td>Acquisition – one time charges</td>
<td>$0.21</td>
</tr>
<tr>
<td>Non-GAAP diluted earnings per share</td>
<td>$1.00 - $1.05</td>
</tr>
</tbody>
</table>
## Second Quarter FY2017 Financial Results

*Beat Guidance on Both Top and Bottom Line*

<table>
<thead>
<tr>
<th></th>
<th>2Q17 Actual Results</th>
<th>2Q16 Actual Results</th>
<th>YoY Growth</th>
<th>Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$196.5</td>
<td>$193.3</td>
<td>2%</td>
<td>$188 - $190 million</td>
</tr>
<tr>
<td>GAAP EPS</td>
<td>$0.09</td>
<td>$0.50</td>
<td>(82%)</td>
<td>$0.06 - $0.08</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$0.26</td>
<td>$0.45</td>
<td>(42%)</td>
<td>$0.23 - $0.25</td>
</tr>
</tbody>
</table>

* Based on higher than anticipated closing costs in the quarter due to the earlier than expected closing of the Assurex acquisition
## Key Accomplishments in 2Q17

### Major Progress on Three Key Strategic Imperatives

<table>
<thead>
<tr>
<th>Strategic Imperative</th>
<th>Accomplishment</th>
</tr>
</thead>
</table>
| Continued Leadership in an Expanding Hereditary Cancer Market | • Grew hereditary cancer revenue by 3% sequentially  
• Oncology volume up sequentially reversing 18 month trend  
• Signed agreement with Highmark Blue Cross Blue Shield  
• 65% of revenue under long-term contract; in network with >95% of plans |
| Diversify Revenue with New Products                      | • Non-hereditary cancer testing reached 67% of volume and 27% of revenue  
• GeneSight volume up 61% and revenue up 47% YoY  
• Anticipate completing enrollment early in major prospective clinical utility study for GeneSight  
• Received draft LCD for favorable intermediate prostate cancer patients for ProLaris  
• SOLO2 study provides further validation for BRACAnalysis CDx  
• Submission of PMA for myChoice HRD  
• EndoPredict payer coverage now >x million lives  
• myPath Melanoma dossier completed |
| Grow Kit Products in Major International Geographies     | • International revenue reached 5% of sales compared to <1% three years ago  
• EndoPredict revenue grew 78% year-over-year following key reimbursement wins in France and Germany  
• Signed companion diagnostic agreement with AstraZeneca in Japan and Latin America |
## Fiscal Second-Quarter 2017 Revenue By Product

### Achieved Highest Revenue in Last Three Years

(in millions)

<table>
<thead>
<tr>
<th>Product</th>
<th>2Q17</th>
<th>2Q16</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary Cancer</td>
<td>$143.9</td>
<td>$165.6</td>
<td>(13%)</td>
</tr>
<tr>
<td>GeneSight</td>
<td>$21.7</td>
<td>NA*</td>
<td>NM</td>
</tr>
<tr>
<td>Vectra DA</td>
<td>$10.7</td>
<td>$11.3</td>
<td>(5%)</td>
</tr>
<tr>
<td>Prolaris</td>
<td>$3.1</td>
<td>$1.9</td>
<td>63%</td>
</tr>
<tr>
<td>EndoPredict</td>
<td>$1.6</td>
<td>$0.9</td>
<td>78%</td>
</tr>
<tr>
<td>Other</td>
<td>$2.9</td>
<td>$2.9</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Total Molecular Diagnostic Revenue</strong></td>
<td><strong>$183.9</strong></td>
<td><strong>$182.6</strong></td>
<td><strong>1%</strong></td>
</tr>
<tr>
<td>Pharmaceutical &amp; Clinical Services</td>
<td>$12.6</td>
<td>$10.7</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$196.5</strong></td>
<td><strong>$193.3</strong></td>
<td><strong>2%</strong></td>
</tr>
</tbody>
</table>

* Prior to the completion of the Assurex Health acquisition
## Fiscal Second-Quarter Financial Results

<table>
<thead>
<tr>
<th>(in millions except per share data)</th>
<th>2Q17</th>
<th>2Q16</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$196.5</td>
<td>$193.3</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>$152.1</td>
<td>$152.7</td>
<td>(0%)</td>
</tr>
<tr>
<td><strong>Gross Margin</strong></td>
<td>77.4%</td>
<td>79.0%</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Operating Income</strong></td>
<td>$13.2</td>
<td>$45.2</td>
<td>(71%)</td>
</tr>
<tr>
<td><strong>Adjusted Operating Income</strong></td>
<td>$23.6</td>
<td>$48.4</td>
<td>(51%)</td>
</tr>
<tr>
<td><strong>Adjusted Operating Margin</strong></td>
<td>12.0%</td>
<td>25.0%</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>$5.9</td>
<td>$37.1</td>
<td>(84%)</td>
</tr>
<tr>
<td><strong>Diluted EPS</strong></td>
<td>$0.09</td>
<td>$0.50</td>
<td>(82%)</td>
</tr>
<tr>
<td><strong>Adjusted EPS</strong></td>
<td>$0.26</td>
<td>$0.45</td>
<td>(42%)</td>
</tr>
</tbody>
</table>
3Q17 and FY17 Financial Guidance
Narrowing Financial Guidance Within The Previous Range

<table>
<thead>
<tr>
<th>Metric</th>
<th>Fiscal Third-Quarter 2017</th>
<th>Fiscal Year 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$188 to $190 million</td>
<td>$745 to $755 million</td>
</tr>
<tr>
<td>GAAP Diluted EPS</td>
<td>$0.08 to $0.10</td>
<td>$0.31 to $0.36</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$0.23 to $0.25</td>
<td>$1.00 to $1.05</td>
</tr>
</tbody>
</table>

For additional information on GAAP to non-GAAP reconciliation see: [https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/](https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/)
Oncology Sees Volume Growth in 2Q17

Sales Force Productivity and New Strategies Leading to Positive Momentum

- ION and U.S. Oncology agreements
- Sales force productivity
- Launch of customizable panels

Average Oncology Test Demand Per Business Day
Myriad Remains In-Network With 95% of Plans

Physicians and Patients Continue To Demand Myriad’s Differential Quality

As out-of-network provider:

- Physicians continue to demand highest quality test
- Myriad maintains >80% of historic volume
- Typically reimbursed at 60% to 80% of list price
Substantial Diversification in Testing Volumes

> Two Thirds of Volume Attributed to Non-Hereditary Cancer Tests

FY13

- ≈180,000 tests
- 99% Hereditary Cancer

FY17E

- ≈600,000 tests
- 33% Hereditary Cancer

CAGR 35%
Reimbursement Will Drive Significant Leverage

$620M Annual New Product Revenue With Full Reimbursement

Current Revenue Run Rate at Full Reimbursement

- Prolaris: $50M
- Vectra DA: $90M
- GeneSight: $460M
- EndoPredict: $20M
- Combined: $620M
Landmark GeneSight Study Near Completion

Study Will Enhance Already Strong Clinical Utility Data Around GeneSight

Mean Improvement in HAM-D17

- 14.9%
- 4%
- 3%
- 3%
- 6%
- 0%
- 2%
- 4%
- 6%
- 8%
- 10%
- 12%
- 14%
- 16%

**FDA Approved Medications**

- 3 Previous Clinical Utility Studies
- Escitalopram vs. Citalopram
- Fluoxetine vs. Paroxetine
- Sertraline vs. Fluoxetine
- Venlafaxine vs. Fluoxetine
- 1,200 Patient Prospective Study

*Sources: FDA summary bases of approvals
Strong New Health Economic Data For GeneSight
Mounting Evidence Supporting Substantial Cost Savings

Year One Cost Savings With GeneSight

- Medco and Union Health Services Studies: $2,000
- NEI Health Economic Study: $8,000
- United Healthcare, Anthem & Humana Payer Demonstration Projects: $0

Sources:
Data presented at the Neuroscience Education Institute Annual Conference 2016
Most MDD Patients are Seen in Primary Care

Significant Opportunity to Leverage Large Preventive Care Sales Team

TREATING PHYSICIAN FOR PATIENTS WITH MDD

- Most MDD patients are seen by primary care consisting of general practice, internal medicine and OB GYNs
- Top 16,000 primary care physicians and OB GYN channel order almost half of the prescriptions for MDD

| 13,600 High Volume Psychiatrists |
| Other 35,000 Psychiatrists |
| Other |
| >200,000 Primary Care and Other |
| 16,000 High Volume Primary Care |

Target: 30k high volume physicians account for 50% of MMD market
Data Supports Vectra DA’s Ability to Predict RP
Correct Analysis of AMPLE Study Further Adds to This Claim

**Sources:**
Vectra DA Predictive of Therapy Response
Patients With a Low Vectra Score Do Substantially Better on Low-Cost Therapy

Low Vectra DA Score

- Rate of Response: 88%
- p-value: 0.006

High Vectra DA Score

- Rate of Response: 35%
- p-value: 0.04

Draft LCD Would Expand Coverage For Prolaris
50% of Prostate Cancer Patients (>100,000/yr) Would be Covered

United States Prolaris Insurance Coverage

- Medicare
- Medicare (Favorable Intermediate)
- Medicare Non-Covered
- Commercial Non-Covered
- Commercial Covered

200,000 localized prostate cancer patients
Ramping Payer Coverage for EndoPredict

Now Covered by Plans Representing 70 Million Lives

U.S. EndoPredict Insurance Coverage

- Submit dossier to Medicare in Q317
- Favorable recommendation from BCBS tech assessment committee Evidence Street
- Coverage decisions from payers representing 70 million lives
Final myPath Melanoma Studies Accepted for Publication

*Dossier To Be Submitted to Medicare and Private Payers by End of FY17*

### myPath Melanoma Diagnostic Accuracy

<table>
<thead>
<tr>
<th>Validation</th>
<th>Pre-Test</th>
<th>Post-Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>2</td>
<td>92%</td>
<td>92%</td>
</tr>
<tr>
<td>3</td>
<td>95%</td>
<td>95%</td>
</tr>
</tbody>
</table>

(n=437 patients, n=736 patients, n=182 patients)

### myPath Melanoma Clinical Utility

<table>
<thead>
<tr>
<th></th>
<th>Pre-Test</th>
<th>Post-Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indeterminate</td>
<td>80%</td>
<td>38%</td>
</tr>
<tr>
<td>Malignant</td>
<td>9%</td>
<td>22%</td>
</tr>
<tr>
<td>Benign</td>
<td>11%</td>
<td>41%</td>
</tr>
</tbody>
</table>

(n=218 patients)

### Multiple PARP Clinical Studies to Report in CY17

**8 Additional Pivotal Clinical Study Results Expected**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of Studies</th>
<th>First Data Expected</th>
<th>Total Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER2- metastatic breast cancer</td>
<td>3</td>
<td>AZN olaparib data reported</td>
<td>160,000</td>
</tr>
<tr>
<td>Neoadjuvant TNBC</td>
<td>1</td>
<td>Jun. 2017</td>
<td>70,000</td>
</tr>
<tr>
<td>Other ovarian</td>
<td>3</td>
<td>Mar. 2017</td>
<td>50,000</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>1</td>
<td>Dec. 2017</td>
<td>100,000</td>
</tr>
</tbody>
</table>

**Total** 380,000
International Revenue Contributing to Growth

Significant Progress Toward Achieving Strategic Goals

Goal to have international product revenue comprise 10% of sales
Diagnostics Are the Keystone for Personalized Medicine
Focused on Six Medical Specialties with Over $200B in Waste

*$Eliminating Waste in U.S. Healthcare
**Clinical Lab Products Magazine – “The Value of Diagnostics”

≈$700B in U.S. Healthcare Spending

Diagnostics represent 3% of spend but drive 70% of healthcare decision making**